Cooperative Agreement U01CA300847
Award Date 8/20/25
Completion Date 7/31/30
Dollars Obligated $678K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- This $410,115 Project Grant was awarded by the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), to the University of California, San Diego (UC San Diego) to support research aimed at improving preclinical models of metastatic pancreatic cancer. The research project seeks to understand how the collagen-rich tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) drives metastasis and treatment resistance, and to develop a synthetic 3D high density...
- This Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,281,520.00 in funding to The Leland Stanford Junior University to conduct research on the fundamental biological mechanisms of cancer metastasis, organ tropism, and immune evasion. The project aims to integrate genetic barcoding with single-cell profiling to uncover the key molecular drivers underlying metastatic fitness and diverse cancer cell states in pancreatic ductal...
- This $667,118 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The project will focus on studying the role of key lysosomal factors, including PLBD1 and LGMN, that are essential for the survival and growth of pancreatic ductal...
- This $5,041,790 cooperative agreement award from the National Cancer Institute (NCI), under the Cancer Centers Support Grants program (CFDA 93.397), will fund research projects at the University of California, San Francisco (UCSF) to improve cancer health disparities. The key products and services to be delivered include: Three translational cancer health disparities research projects focused on meningioma, prostate cancer, and breast cancer. The projects aim to evaluate the interplay of...
- This $680,507 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of California, San Francisco. The grant aims to elucidate mechanisms of cancer persister cell rewiring and identify druggable targets to eradicate persistence in KRAS-mutant non-small cell lung cancer. The key objectives are to: 1) illuminate signals that promote persistence in physiological contexts, 2) identify and validate targets that inhibit...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This $642,755 Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), supports research by The Institute for Cancer Research (ICR) to investigate the role of the protein Anoctamin 6 (ANO6) in disrupting the trogocytosis process that enables cancer-associated fibroblasts to transfer lipids to pancreatic ductal adenocarcinoma (PDAC) tumor cells. The research aims to elucidate how ANO6 activity is regulated in the...
- This $745,320 Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will fund a research project conducted by the Salk Institute for Biological Studies in La Jolla, CA. The project aims to investigate how omega-3 and omega-6 fatty acids regulate inflammatory signals in pancreatic cancer, with the goal of understanding how to resolve chronic inflammation and prevent progression to pancreatic ductal adenocarcinoma (PDAC). The 5-year project will...
- The National Cancer Institute (NCI) awarded a $654,197 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation (Massachusetts General Hospital) to develop and characterize patient-derived xenograft (PDX) tumor models that represent the major molecular subtypes of pancreatic ductal adenocarcinoma (PDAC). The grant aims to: 1) define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies, 2) elucidate the contribution of...
- The Department of the Army Medical Command awarded a $5.3 million cooperative agreement to the Regents of the University of California, San Francisco for the period of August 1, 2022 through July 31, 2026. The award will support the University's efforts to prevent lethal metastatic breast cancer through the identification and eradication of clinically relevant disseminated tumor cells. This cooperative agreement was awarded under the Military Medical Research and Development program (CFDA...